Replies to post #90 on Affymetrix Inc. (AFFX)

[surf1944]

6:06AM Affymetrix sees Q1 revs below consensus (AFFX) 4.66 : Co issues downside guidance for Q1 (Mar), sees Q1 revs of ~ $78 mln, including rev of ~ $19 mln from eBioscience, vs. $83.34 mln Capital IQ Consensus Estimate. "Our revenues for the first quarter were below expectations, primarily due to continued headwinds in our gene expression business across all regions, in particular Japan, where we came in significantly short of plan. Our genotyping and cytogenetics product lines generated solid growth for the quarter as compared to 2012 and eBioscience also had modest growth from the first quarter of last year. As reported earlier, we ended the quarter with a major win, securing the largest biobank genotyping study to date."